Pipeline Insight: Leukemias Underserved patient populations offer potential for market growth
Datamonitor, March 2010, Pages: 238
Introduction
Despite major advances in treatment in the last decade, a considerable percentage of the leukemia population still has high unmet needs. Some key oncology companies have entered the leukemias market fairly recently while others are pursuing late-phase development in this indication, hoping to exploit the commercial potential of patient subgroups underserved by existing treatment options.
Scope
-Forecast sales of the drugs in late-phase development for leukemia in the seven major markets over the period 2010 to 2019
-In-depth analysis for all leukemia drugs in late-phase development, including trial data, SWOT analysis and clinical and commercial potential
-Segmentation and analysis of the leukemia pipeline by developmental phase, class and indication
-Insight and analysis of leukemia market potential including epidemiology, patient segmentation, unmet needs and target product profiles
Highlights
Despite high cure rates in some forms of leukemia, certain groups of patients still have high unmet needs. Drug developers are targeting increasingly defined subsets of patients with high unmet need in order to establish a market for their products. Examples include elderly patients and patients with certain genetic characteristics.
Chronic lymphocytic leukemia (CLL) offers the greatest potential. Datamonitor forecasts the three drugs in late-phase development to achieve total sales of $938m in 2019. This stems from the large size of the target patient populations and a lack of effective treatment options in these patient subgroups, which will drive high market penetration.
A number of late-phase drugs will have a notable impact on the leukemia market as they go some way towards addressing some of the remaining unmet needs. These agents include Revlimid (lenalidomide; Celgene), RG7159 (obinutuzumab; Glycart/Roche/Genentech/Biogen Idec/Chugai) and bosutinib (PF-5208763; Pfizer).
Reasons to Purchase
-Justify go/no-go decisions on the basis of potential return on investment
-Identifying licensing opportunities based on company portfolio and market needs
-Use product profiles to aid pricing and reimbursement decisions
Overview
Catalyst
Summary
Executive Summary
Strategic scoping and focus
Datamonitor insight into the disease market
Contributing experts
Related reports
Upcoming related reports
1. Pipeline Overview and Dynamics
Key findings
Pipeline overview
Pipeline summary
Acute myeloid leukemia is the form of leukemia most targeted by drug developers
Targeted therapies account for over half of leukemia drugs in clinical development
Comparative forecasts
Drugs in late-phase development for leukemias will achieve combined sales of $1.9 billion by 2019
Key companies involved in the leukemias pipeline
Novartis
Roche
Key R&D company strategies
Drug developers are targeting increasingly defined subsets of patients
2. R&D Approach
Key findings
Clinical trial design in leukemia
Patient selection
Increasingly significant in the era of targeted treatment
Clinical trial duration
Sufficient follow-up is necessary to establish true clinical benefit
The advent of novel therapies
Diversity of targeted therapies will require an evolution in clinical trial design
Clinical trial endpoints in leukemia
Most oncology clinical trials designate multiple endpoints
Survival
Quality of life
Response rates
Toxicity
Time to progression
3. Acute lymphoblastic leukemia
Key findings
Disease overview - market potential
Definition of acute lymphoblastic leukemia (ALL)
ALL is a group of disorders that result from aberrant proliferation and differentiation of lymphoblasts
Genetic alterations provide insight into the pathogenesis of ALL
Non-specific syndromes are common in ALL
Patient segmentation
The classification of ALL is still evolving
Patients are stratified according to risk
Response to therapy: minimal residual disease is a critical prognostic factor
Epidemiology
Incidence of ALL will reach over 11,000 in the seven major markets by 2019
Current treatment options
Remission-induction
Consolidation treatment
Maintenance treatment
Current comparator therapies
Unmet need in ALL
More effective therapies are required for adult ALL, particularly for relapse
Philadelphia chromosome-positive patients remain a patient subset with high unmet need despite new therapies
More research is needed for elderly ALL patients
Prognostic markers are required for risk-adapted therapeutic strategies
Target product profiles versus current level of attainment
Induction therapy
Relapse therapy
Pipeline analysis and forecasts
Pipeline summary
Comparative forecasts
Graspa (erythrocyte-encapsulated L-asparaginase; ERYtech)
Drug overview
Drug profile
Key historical events
Clinical trial data
Phase II data suggest that Graspa is better tolerated than native L-asparaginase, while inducing similar asparagine depletion
SWOT analysis
Clinical and commercial attractiveness
Limited evidence of clinical efficacy makes it difficult to comment on Graspa's clinical potential
A favorable toxicity profile alone may not be sufficient for Graspa to capture significant market share
Forecasts to 2019
Marqibo (liposomal vincristine; Hana Biosciences)
Drug overview
Drug profile
Key historical events
Clinical trial data
Marqibo shows promising evidence of efficacy in heavily pretreated ALL
SWOT analysis
Datamonitor's drug assessment summary for Marqibo
Clinical and commercial attractiveness
Marqibo will only partially address the need for more effective salvage regimens in ALL
Data from a small single-arm study may be insufficient to support approval and drive uptake of Marqibo
Forecasts to 2019
Rituxan/MabThera (rituximab; Biogen Idec/Roche/Genentech/Zenyaku Kogyo/Chugai)
Drug overview
Drug profile
Key historical events
Clinical trial data
Rituxan/MabThera plus HyperCVAD shows promising evidence of efficacy in younger patients with CD20-positive ALL
Rituxan/MabThera plus HyperCVAD also shows promising efficacy in Burkitt-type ALL, particularly in elderly patients
SWOT analysis
Datamonitor drug assessment summary for Rituxan
Clinical and commercial attractiveness
Phase II data point to Rituxan/MabThera's promising potential in ALL, but provoke several questions
The use of Rituxan/MabThera in ALL may remain off-label for the foreseeable future
Forecasts to 2019
4. Acute myeloid leukemia
Key findings
Disease overview - market potential
Definition of acute myeloid leukemia (AML)
AML is a disease of older age
Symptoms can vary for AML patients
Patient segmentation
Two classification systems are used in AML
Cytogenetics is the most important prognostic factor
Age is a major determinant of survival
Secondary AML patients have particularly poor prognosis
Epidemiology
Incidence of AML will reach over 31,000 in the seven major markets by 2019, driven by population aging
Current treatment options
Induction treatment
Post-induction treatment
Consolidation treatment
Relapse treatment
Current comparator therapies
Unmet need in AML
More effective and tolerable therapies are required for AML, particularly in older patients
HSCT remains an underutilized procedure
Molecular markers may help improve risk-adapted therapeutic strategies
Target product profiles versus current level of attainment
Induction therapy
Consolidation therapy
Relapse therapy
Pipeline analysis and forecasts
Pipeline summary
Comparative forecasts
AS1413 (amonafide; Antisoma)
Drug overview
Drug profile
Key historical events
Clinical trial data
Antisoma has amended the primary endpoint in AS1413's pivotal Phase III study
Phase II study shows encouraging evidence of activity in secondary AML
SWOT analysis
Datamonitor drug assessment summary for AS1413
Clinical and commercial attractiveness
AS1413 has the potential to address unmet need in a difficult-to-treat patient population
AS1413's potential in the wider AML population is uncertain
Forecasts to 2019
Clolar/Evoltra (clofarabine; Genzyme)
Drug overview
Drug profile
Key historical events
Clinical trial data
Phase II data in newly diagnosed elderly AML insufficient to support label extension for Clolar
Phase II data show potential of Clolar in combination with low-dose cytarabine
SWOT analysis
Datamonitor drug assessment summary for Clolar/Evoltra
Clinical and commercial attractiveness
Clolar's unsuccessful bid for accelerated approval in AML is a double blow to Genzyme
Clolar could receive off-label use in the absence of label expansion
Forecasts to 2019
Dacogen (decitabine; Eisai)
Drug overview
Drug profile
Key historical events
Clinical trial data
Dacogen has shown promising evidence of efficacy in previously untreated elderly AML patients
SWOT analysis
Datamonitor drug assessment summary for Dacogen
Clinical and commercial attractiveness
Dacogen's low toxicity could be a major driver of uptake
Vidaza will be Dacogen's principal competitor in the AML market
Forecasts to 2019
Midostaurin (PKC412; Novartis)
Drug overview
Drug profile
Key historical events
Clinical trial data
Midostaurin shows promising evidence of efficacy in AML patients with wild-type and mutant Flt-3
SWOT analysis
Datamonitor drug assessment summary for midostaurin
Clinical and commercial attractiveness
Targeting younger AML patients offers lower commercial potential for midostaurin
Novartis's capabilities in niche hematological indications will boost midostaurin's commercial potential
Forecasts to 2019
PR1 peptide antigen vaccine (The Vaccine Company)
Drug overview
Drug profile
Key historical events
Clinical trial data
PR1 peptide antigen induced immune and clinical responses in patients with myeloid hematological malignancies in Phase I/II trial
SWOT analysis
Datamonitor drug assessment summary for PR1 peptide antigen
Clinical and commercial attractiveness
PR1 peptide antigen could fulfill the unmet need for more tolerable treatment options in elderly AML patients
As a therapeutic vaccine, PR-1 peptide antigen will face particular barriers to successful commercialization
Forecasts to 2019
5. Chronic lymphocytic leukemia
Key findings
Disease overview - market potential
Definition of chronic lymphocytic leukemia (CLL)
CLL is an incurable disease characterized by an accumulation of mature B-lymphocytes
The definition of CLL has recently changed
The etiology of CLL is poorly understood
Patient segmentation
Rai and Binet staging systems are used to stage CLL
Molecular markers are used to identify high-risk patients
Epidemiology
CLL will remain the most commonly diagnosed leukemia in the seven major markets through to 2019
Current treatment options
Physicians commonly initiate first-line treatment after a period of observation
First-line treatment
Second- and third-line treatment
Current comparator therapy
Rituxan/MabThera (rituximab; Biogen Idec/Genentech/Roche/Chugai/Zenyaku Kogyo)
Unmet need in CLL
More effective therapies are needed for relapsed and refractory CLL
CLL still lacks curative treatment options for the majority of patients
More tolerable treatment options are needed for elderly patients
Target product profiles versus current level of attainment
First-line therapy
Second-line therapy
Pipeline analysis and forecasts
Pipeline summary
Comparative forecasts
Alvocidib (flavopiridol; Sanofi-Aventis)
Drug overview
Drug profile
Key historical events
Clinical trial data
Optimization of alvocidib's dosing schedule has reawakened interest in the drug
Single-agent alvocidib induces responses in heavily pretreated CLL patients with unfavorable cytogenetics
Alvocidib has also shown promise in early stages studies in combination with fludarabine and Rituxan
SWOT analysis
Datamonitor drug assessment summary for alvocidib
Clinical and commercial attractiveness
Alvocidib has shown encouraging signs of activity in difficult-to-treat patients
Sanofi-Aventis will have to overturn negative perceptions of alvocidib's clinical development in CLL
Arzerra could prove to be a major competitor for alvocidib, given its more favorable toxicity profile
Forecasts to 2019
Revlimid (lenalidomide; Celgene)
Drug overview
Drug profile
Key historical events
Clinical trial data
Celgene has initiated an extensive clinical development program for Revlimid in CLL
Low dose single-agent Revlimid shows promising activity and tolerability in heavily pretreated CLL
Early Phase II data show that single-agent Revlimid has favorable toxicity profile in previously untreated elderly CLL
Revlimid may be more effective when combined with Rituxan
SWOT analysis
Datamonitor drug assessment summary for Revlimid
Clinical and commercial attractiveness
Revlimid has the potential to fill a niche in the CLL market
Revlimid's favorable toxicity profile could be an important attribute in the maintenance setting
Potential for long-term use could boost Revlimid's commercial potential in CLL
Forecasts to 2019
RG7159 (obinutuzumab; Glycart/Roche/Genentech/Biogen Idec/Chugai)
Drug overview
Drug profile
Key historical events
Clinical trial data
There is currently minimal reported evidence of RG7159's clinical efficacy
SWOT analysis
Datamonitor drug assessment summary for RG7159
Clinical and commercial attractiveness
Roche has avoided the risk of cannibalizing Rituxan's market share in CLL
The design of RG7159's pivotal trial is high-risk, but necessary in order to drive notable uptake
Forecasts to 2019
6. Chronic myeloid leukemia
Key findings
Disease overview - market potential
Definition of chronic myeloid leukemia (CML)
CML is characterized by a single genetic aberration
CML patients are commonly asymptomatic at presentation
CML has an unknown etiology
Patient segmentation
CML has a triphasic or biphasic disease course
Epidemiology
Annual CML incidence will rise to nearly 13,000 in the seven major markets by 2019
Improving treatment outcomes will drive significant increases in the prevalence of CML
The market potential for newly-diagnosed CML will grow markedly between 2010 and 2019
Current treatment options
Small molecule Bcr-Abl tyrosine kinase inhibitors dominate the treatment of CML
Treatment of newly-diagnosed CML
Gleevec-refractory CML
Current comparator therapy
Gleevec/Glivec (imatinib; Novartis)
Unmet need in CML
Resistance to Bcr-Abl tyrosine kinase inhibitors is an area of high unmet need
Blast crisis lacks effective treatment options but is not a commercially attractive indication
Despite good treatment outcomes for the majority of chronic phase patients, there is room for improvement
Target product profiles versus current level of attainment
Newly diagnosed CML
Gleevec refractory/intolerant CML
Pipeline analysis and forecasts
Pipeline summary
Comparative forecasts
Bosutinib (PF-5208763; Pfizer)
Drug overview
Drug profile
Key historical events
Clinical trial data
Bosutinib has shown promising activity and a favorable toxicity profile in Gleevec-resistant/intolerant CML
SWOT analysis
Datamonitor drug assessment summary for bosutinib
Clinical and commercial attractiveness
Bosutinib could struggle to penetrate a crowded first-line market ...
...although its promising safety profile could allow Pfizer to position it effectively in the CML market
Forecasts to 2019
Omapro (omacetaxine mepesuccinate; ChemGenex/Hospira)
Drug overview
Drug profile
Key historical events
Clinical trial data
Omapro shows promising activity in Gleevec-resistant patients with the T315I mutation but ODAC vote could delay approval
Omapro also shows activity in patients refractory/intolerant to at least two tyrosine kinase inhibitors
SWOT analysis
Datamonitor drug assessment summary for Omapro
Clinical and commercial attractiveness
Omapro may address one of the largest remaining areas of unmet in CML in the Gleevec era
Prospects of approval remain uncertain for Omapro
Advances in first-line therapy could threaten Omapro's commercial potential
Forecasts to 2019
Bibliography
Journals
Websites
Datamonitor reports
Other
APPENDIX
Methodology
Datamonitor forecast methodology
Epidemiology forecasts
Product forecasts
Datamonitor drug assessment scorecard
Contributing experts
About Datamonitor
About Datamonitor Healthcare
About the Disease analysis team
Datamonitor consulting
Disclaimer
List of Tables
Table 1: Drugs in late-phase clinical development for leukemia in the seven major pharmaceutical markets, 2010
Table 2: Sales forecasts for drugs in late-phase clinical development for leukemia across the seven major markets, 2010-19 ($m)
Table 3: Novartis's portfolio of marketed and pipeline leukemia drugs, 2010
Table 4: Roche's portfolio or marketed and pipeline leukemia drugs, 2010
Table 5: The French-American-British system for the classification of acute lymphoblastic leukemia (ALL)
Table 6: Crude incidence rates of acute lymphoblastic leukemia (ALL) per 100,000 population in the seven major pharmaceutical markets, 2002
Table 7: Forecast incidence of acute lymphoblastic leukemia (ALL) in the seven major pharmaceutical markets, 2002-2019
Table 8: Leading agents for acute lymphocytic leukemia (ALL), 2010
Table 9: Minimum acceptable product profile (MAPP) and target product profile (TPP) for first-line treatment of adult acute lymphoblastic leukemia (ALL), 2010
Table 10: Minimum acceptable product profile (MAPP) and target product profile (TPP) for the treatment of relapsed adult acute lymphoblastic leukemia (ALL), 2010
Table 11: Drugs in late-phase clinical development for acute lymphoblastic leukemia (ALL), 2010
Table 12: Forecast assumptions for drugs in late-phase clinical development for acute lymphoblastic leukemia (ALL) across the seven major markets, 2010
Table 13: Sales forecasts for drugs in late-phase clinical development for acute lymphoblastic leukemia across the seven major markets, 2010-19 ($m)
Table 14: Graspa - drug profile, 2010
Table 15: Graspa: key historical events, 2004-2010
Table 16: Clinical development of Graspa in acute lymphoblastic leukemia (ALL), 2010
Table 17: Marqibo - drug profile, 2010
Table 18: Marqibo: key historical events, 2000-2010
Table 19: Clinical development of Marqibo in acute lymphoblastic leukemia (ALL), 2010
Table 20: Sales forecast for Marqibo in acute lymphoblastic leukemia (ALL) across the seven major markets, 2010-19 ($m)
Table 21: Rituxan/MabThera - drug profile, 2010
Table 22: Rituxan/MabThera: key historical events, 1997-2010
Table 23: Clinical development of Rituxan/MabThera in acute lymphoblastic leukemia (ALL), 2010
Table 24: Sales forecast for Rituxan in acute lymphoblastic leukemia (ALL) across the seven major markets, 2010-19 ($m)
Table 25: French-American-British classification of acute myeloid leukemia (AML)
Table 26: Crude incidence rates of acute myeloid leukemia (AML) per 100,000 population in the seven major pharmaceutical markets, 2002
Table 27: Forecast incidence of acute myeloid leukemia (AML) in the seven major pharmaceutical markets, 2002-2019
Table 28: Leading agents for acute myeloid leukemia (AML), 2010
Table 29: Minimum acceptable product profile (MAPP) and target product profile (TPP) for first-line treatment of adult acute myeloid leukemia (AML), 2010
Table 30: Minimum acceptable product profile (MAPP) and target product profile (TPP) for consolidation treatment of adult acute myeloid leukemia (AML) in first remission, 2010
Table 31: Minimum acceptable product profile (MAPP) and target product profile (TPP) for first-line treatment of adult acute myeloid leukemia (AML), 2010
Table 32: Drugs in late-phase clinical development for acute myeloid leukemia (AML), 2010
Table 33: Forecast assumptions for drugs in late-phase clinical development for acute myeloid leukemia (AML) across the seven major markets, 2010 (1 of 2)
Table 34: Forecast assumptions for drugs in late-phase clinical development for acute myeloid leukemia (AML) across the seven major markets, 2010 (2 of 2)
Table 35: Sales forecasts for drugs in late-phase clinical development for acute myeloid leukemia across the seven major markets, 2010-19 ($m)
Table 36: AS1413 - drug profile, 2010
Table 37: AS1413: key historical events, 2003-2010
Table 38: Clinical development of AS1413 in acute myeloid leukemia, 2010
Table 39: Sales forecast for AS1413 in acute myeloid leukemia (AML) across the seven major markets, 2010-19 ($m)
Table 40: Clolar/Evoltra - drug profile, 2010
Table 41: Clolar/Evoltra: key historical events, 1998-2010
Table 42: Clinical development of Clolar/Evoltra in acute myeloid leukemia (AML), 2010
Table 43: Sales forecast for Clolar/Evoltra in acute myeloid leukemia across the seven major markets, 2010-19 ($m)
Table 44: Dacogen - drug profile, 2010
Table 45: Dacogen: key historical events, 1999-2010
Table 46: Clinical development of Dacogen in acute myeloid leukemia (AML), 2010
Table 47: Sales forecast for Dacogen in acute myeloid leukemia (AML) across the seven major markets, 2010-19 ($m)
Table 48: Midostaurin - drug profile, 2010
Table 49: Midostaurin: key historical events, 2002-2010
Table 50: Clinical development of midostaurin in acute myeloid leukemia (AML), 2010
Table 51: Sales forecast for midostaurin in acute myeloid leukemia (AML) across the seven major markets, 2010-19 ($m)
Table 52: PR1 peptide antigen - drug profile, 2010
Table 53: PR1 peptide antigen: key historical events, 1999-2010
Table 54: Clinical development of PR1 peptide antigen, 2010
Table 55: Sales forecast for PR1 peptide antigen vaccine in acute myeloid leukemia (AML) across the seven major markets, 2010-19 ($m)
Table 56: The Rai staging system for chronic lymphocytic leukemia (CLL)
Table 57: The Binet staging system for chronic lymphocytic leukemia (CLL)
Table 58: Crude incidence rates of chronic lymphocytic leukemia (CLL) per 100,000 population in the seven major pharmaceutical markets, 2002
Table 59: Forecast incidence of chronic lymphocytic leukemia (CLL) in the seven major pharmaceutical markets, 2002-2019
Table 60: Leading agents for chronic lymphocytic leukemia (CLL), 2010
Table 61: Rituxan/MabThera (rituximab) - drug profile, 2010
Table 62: Minimum acceptable product profile (MAPP) and target product profile (TPP) for first-line treatment of chronic lymphocytic leukemia (CLL), 2010
Table 63: Minimum acceptable product profile (MAPP) and target product profile (TPP) for second-line treatment of chronic lymphocytic leukemia (CLL), 2010
Table 64: Drugs in late-phase clinical development for chronic lymphocytic leukemia (CLL), 2010
Table 65: Forecast assumptions for drugs in late-phase clinical development for chronic lymphocytic leukemia (CLL) across the seven major markets, 2010
Table 66: Sales forecasts for drugs in late-phase clinical development for chronic lymphocytic leukemia (CLL) across the seven major markets, 2010-19 ($m)
Table 67: Alvocidib - drug profile, 2010
Table 68: Alvocidib: key historical events, 2004-2010
Table 69: Clinical development of alvocidib in chronic lymphocytic leukemia (CLL), 2010
Table 70: Phase I dose-escalating study of alvocidib in combination with chemotherapy in patients with indolent B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)
Table 71: Sales forecast for alvocidib in chronic lymphocytic leukemia (CLL) across the seven major markets, 2010-19 ($m)
Table 72: Revlimid - drug profile, 2010
Table 73: Revlimid: key historical events, 2005-2010
Table 74: Clinical development of Revlimid in chronic lymphocytic leukemia (CLL), 2010
Table 75: Sales forecast for Revlimid in chronic lymphocytic leukemia (CLL) across the seven major markets, 2010-19 ($m)
Table 76: RG7159 - drug profile, 2010
Table 77: RG7159: key historical events, 2007-2010
Table 78: Clinical development of RG7159 in chronic lymphocytic leukemia (CLL), 2010
Table 79: Sales forecast for RG7159 in chronic lymphocytic leukemia (CLL) across the seven major markets, 2010-19 ($m)
Table 80: Different definitions of accelerated phase chronic myeloid leukemia (AP-CML), 2010
Table 81: Different definitions of blast crisis chronic myeloid leukemia (BC-CML)
Table 82: Crude incidence rates of chronic myeloid leukemia (CML) per 100,000 population in the seven major pharmaceutical markets, 2002
Table 83: Forecast incidence of chronic myeloid leukemia (CML) in the seven major pharmaceutical markets, 2002-2019
Table 84: Forecast prevalence of chronic myeloid leukemia (CML) in the seven major pharmaceutical markets, 2010-19
Table 85: Number of chronic phase chronic myeloid leukemia (CP-CML) patients in first complete cytogenetic remission (CCyR) receiving a tyrosine kinase inhibitor in the seven major markets, 2010-19
Table 86: Leading agents for chronic myeloid leukemia (CML), 2010
Table 87: Gleevec (imatinib; Novartis) - drug profile, 2010
Table 88: Number of chronic myeloid leukemia (CML) patients developing Gleevec resistance in the seven major pharmaceutical markets, 2010-19
Table 89: Minimum acceptable product profile (MAPP) and target product profile (TPP) for treatment of newly diagnosed chronic phase chronic myeloid leukemia (CP-CML), 2010
Table 90: Minimum acceptable product profile (MAPP) and target product profile (TPP) treatment of Gleevec-refractory/intolerant chronic phase chronic myeloid leukemia (CP-CML), 2010
Table 91: Drugs in late-phase clinical development for chronic myeloid leukemia (CML), 2010
Table 92: Forecast assumptions for drugs in late-phase clinical development for chronic myeloid leukemia (CML) across the seven major markets, 2010
Table 93: Sales forecasts for drugs in late-phase clinical development for chronic myeloid leukemia (CML) across the seven major markets, 2010-19 ($m)
Table 94: Bosutinib - drug profile, 2010
Table 95: Bosutinib: key historical events, 2006-2010
Table 96: Clinical development of bosutinib in chronic myeloid leukemia (CML), 2010
Table 97: Sales forecast for bosutinib in chronic myeloid leukemia (CML) across the seven major markets, 2010-19 ($m)
Table 98: Omapro - drug profile, 2010
Table 99: Omapro: key historical events, 2004-2010
Table 100: Clinical development of Omapro in chronic myeloid leukemia (CML), 2010
Table 101: Sales forecast for Omapro in chronic myeloid leukemia (CML) across the seven major markets, 2010-19 ($m)
Table 102: Datamonitor drug assessment parameters
List of Figures
Figure 1: Number of drugs in clinical development for the four principal subtypes of leukemia, by phase of development, 2010
Figure 2: Number of drugs in clinical development for leukemia, by phase of development and class, 2010
Figure 3: Forecast incidence of acute lymphoblastic leukemia (ALL) in the seven major pharmaceutical markets, 2010-19
Figure 4: Summary of unmet needs in acute lymphoblastic leukemia (ALL), 2010
Figure 5: Datamonitor drug assessment for drugs in late-phase clinical development for acute lymphoblastic leukemia (ALL), 2010
Figure 6: Summary of data from GRASPALL Phase II study of Graspa in relapsed acute lymphoblastic leukemia (ALL)
Figure 7: Graspa - SWOT analysis in acute lymphoblastic leukemia (ALL), 2010
Figure 8: Summary of data from rALLy Phase II study of Marqibo in relapsed acute lymphoblastic leukemia (ALL)
Figure 9: Summary of data from Phase I/II study of Marqibo in relapsed/refractory acute lymphoblastic leukemia (ALL)
Figure 10: Marqibo - SWOT analysis in acute lymphoblastic leukemia (ALL), 2010
Figure 11: Datamonitor drug assessment summary for Marqibo in acute lymphoblastic leukemia (ALL), 2010
Figure 12: Summary of data from Phase II study of Rituxan/MabThera in newly-diagnosed Philadelphia chromosome-negative, CD20-positive precursor B-cell acute lymphoblastic leukemia (ALL)
Figure 13: Summary of data from Phase II study of Rituxan/MabThera in newly-diagnosed Burkitt-type acute lymphoblastic leukemia (ALL)/Burkitt lymphoma
Figure 14: Rituxan/MabThera - SWOT analysis in acute lymphoblastic leukemia (ALL), 2010
Figure 15: Datamonitor drug assessment summary for Rituxan in acute lymphoblastic leukemia (ALL), 2010
Figure 16: Forecast incidence of acute myeloid leukemia (AML) in the seven major pharmaceutical markets, 2010-19
Figure 17: Summary of unmet needs in acute myeloid leukemia (AML), 2010
Figure 18: Datamonitor drug assessment for drugs in late-phase clinical development for acute myeloid leukemia (AML), 2010
Figure 19: Summary of data from Phase II study of AS1413 in secondary acute myeloid leukemia (AML)
Figure 20: AS1413 - SWOT analysis in acute myeloid leukemia (AML), 2010
Figure 21: Datamonitor drug assessment summary for AS1413 in acute myeloid leukemia (AML), 2010
Figure 22: Summary of preliminary data from the 'CLASSIC II' Phase II study of Clolar/Evoltra in newly-diagnosed elderly acute myeloid leukemia (AML) patients
Figure 23: Summary of preliminary data from a Phase II study of Clolar/Evoltra in combination with low-dose cytarabine in newly-diagnosed elderly acute myeloid leukemia (AML) patients
Figure 24: Clolar/Evoltra - SWOT analysis in acute myeloid leukemia (AML), 2010
Figure 25: Datamonitor drug assessment summary for Clolar/Evoltra in acute myeloid leukemia (AML), 2010
Figure 26: Summary of data from Phase II trial of Dacogen in previously untreated elderly acute myeloid leukemia (AML) patients
Figure 27: Summary of data from a multicenter Phase II trial of Dacogen in previously untreated elderly acute myeloid leukemia (AML) patients
Figure 28: Dacogen - SWOT analysis in acute myeloid leukemia (AML), 2010
Figure 29: Datamonitor drug assessment summary for Dacogen in acute myeloid leukemia (AML), 2010
Figure 30: Summary of data from Phase Ib study of midostaurin in newly-diagnosed acute myeloid leukemia (AML)
Figure 31: Midostaurin - SWOT analysis in acute myeloid leukemia (AML), 2010
Figure 32: Datamonitor drug assessment summary for midostaurin in acute myeloid leukemia (AML), 2010
Figure 33: Phase I/II trial results investigating PR1 peptide antigen in mixed myeloid hematological malignancies
Figure 34: PR1 peptide antigen - SWOT analysis in acute myeloid leukemia (AML), 2010
Figure 35: Datamonitor drug assessment summary for PR1 peptide antigen in acute myeloid leukemia (AML), 2010
Figure 36: Characteristic immunophenotype of accumulating malignant B-lymphocytes in chronic lymphocytic leukemia (CLL)
Figure 37: Forecast incidence of chronic lymphocytic leukemia (CLL) in the seven major pharmaceutical markets, 2010-19
Figure 38: Summary of unmet needs in chronic lymphocytic leukemia (CLL), 2010
Figure 39: Datamonitor drug assessment for drugs in late-phase clinical development for chronic lymphocytic leukemia (CLL), 2010
Figure 40: Summary of data from Phase II clinical trial of alvocidib in relapsed/refractory chronic lymphocytic leukemia (CLL)
Figure 41: Alvocidib - SWOT analysis in chronic lymphocytic leukemia (CLL), 2010
Figure 42: Datamonitor drug assessment summary for alvocidib in chronic lymphocytic leukemia (CLL), 2010
Figure 43: Phase II study of Revlimid in relapsed/refractory chronic lymphocytic leukemia (CLL),
Figure 44: Preliminary data from Phase II study of Revlimid as first-line treatment in elderly chronic lymphocytic leukemia (CLL) patients
Figure 45: Preliminary data from Phase II trial of Revlimid plus Rituxan in relapsed/refractory chronic lymphocytic leukemia (CLL)
Figure 46: Revlimid - SWOT analysis in chronic lymphocytic leukemia (CLL), 2010
Figure 47: Datamonitor drug assessment summary for Revlimid in chronic lymphocytic leukemia (CLL), 2010
Figure 48: RG7159 - SWOT analysis in chronic lymphocytic leukemia (CLL), 2010
Figure 49: Datamonitor drug assessment summary for RG7159 in chronic lymphocytic leukemia (CLL), 2010
Figure 50: Forecast incidence of chronic myeloid leukemia (CML) in the seven major pharmaceutical markets, 2010-19
Figure 51: Forecast prevalence of chronic myeloid leukemia (CML) in the seven major pharmaceutical markets, 2010-19
Figure 52: Summary of unmet needs in chronic lymphocytic leukemia (CML), 2010
Figure 53: Datamonitor drug assessment for drugs in late-phase clinical development for chronic myeloid leukemia (CML), 2010
Figure 54: Phase II study of bosutinib in Gleevec-resistant/intolerant chronic myeloid leukemia (CML) in chronic phase
Figure 55: Phase II study of bosutinib in Gleevec-resistant/intolerant chronic myeloid leukemia (CML) in accelerated phase or blast crisis
Figure 56: Bosutinib - SWOT analysis in chronic myeloid leukemia (CML), 2010
Figure 57: Datamonitor drug assessment summary for bosutinib in chronic myeloid leukemia (CML), 2010
Figure 58: Study 202: Interim data from Phase II/III study of Omapro in Gleevec-resistant chronic myeloid leukemia (CML) patients with the T315I mutation
Figure 59: Study 203: Interim data from Phase II/III study of Omapro in chronic myeloid leukemia (CML) patients resistant/intolerant to at least two tyrosine kinase inhibitors
Figure 60: Omapro - SWOT analysis in chronic myeloid leukemia (CML), 2010
Figure 61: Datamonitor drug assessment summary for Omapro in chronic myeloid leukemia (CML), 2010
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
